BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...Inc. (NASDAQ:ARDX), Epizyme Inc. (NASDAQ:EPZM) and Mersana Therapeutics Inc. (NASDAQ:MRSN). Among private companies, he chairs Cydan Development Inc....
BioCentury | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

...Willem Scheele as CMO. He succeeds interim CMO Shi Yin Foo, who is CMO of Cydan II Inc....
BioCentury | Jan 5, 2019
Finance

Longitude takes a spin with Cydan

...Longitude Capital's first foray into a Cydan Development Inc. spinout came Thursday when Cydan launched Tiburio Therapeutics Inc...
...former Head of Endocrinology R&D Michael Culler will chair Tiburio’s SAB, Ceesay said. Jennie Walters, Staff Writer Cydan II Inc. Ipsen...
BioCentury | Jan 4, 2019
Financial News

Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

...plans to develop for rare neuroendocrine tumors and rare endocrine diseases. Tiburio spun out of Cydan Development Inc....
BioCentury | Jan 4, 2019
Company News

Codiak, Jazz to develop exosomes against tricky oncogenes

...market close. Codiak BioSciences Inc., Cambridge, Mass. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Business: Cancer Jennie Walters Cydan II Inc. Jazz...
BioCentury | Jan 3, 2019
Financial News

Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

...plans to develop for rare neuroendocrine tumors and rare endocrine diseases. Tiburio spun out of Cydan Development Inc....
...be eligible for development and commercial milestones, plus royalties. Ceesay declined to disclose financial terms. Jennie Walters Cydan II Inc. Dopamine...
BioCentury | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

...and nanotechnology at the Technical University of Denmark (Kongens Lyngby, Denmark). Rare genetic disease accelerator Cydan Development Inc....
BioCentury | Oct 20, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...from academia, not-for-profits and industry. CEO Chris Adams told BioCentury the accelerator's new investment vehicle, Cydan II Inc....
...was director of CMC at Ascendis Pharma A/S (NASDAQ:ASND). Cydan Development Inc. , Cambridge, Mass. Chris Lieu IMR-687 VTS-270 Ascendis Pharma A/S Cydan II Inc. Imara...
BioCentury | Oct 20, 2017
Finance

Fast inflections

...Longitude Capital joined Cydan Development Inc. ’s syndicate with the expectation that spinouts from the rare disease accelerator...
...to six additional spinouts, and expects to announce its third newco next year. Virginia Li, Staff Writer Cydan II Inc. Vtesse...
BioCentury | Oct 17, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...from academia, not-for-profits and industry. CEO Chris Adams told BioCentury the accelerator's new investment vehicle, Cydan II Inc....
...Bristol-Myers Squibb Co. (NYSE:BMY) acquired. Svenstrup was director of CMC at Ascendis Pharma A/S (NASDAQ:ASND). Chris Lieu IMR-687 VTS-270 Cydan II Inc. Imara...
Items per page:
1 - 10 of 21
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...Inc. (NASDAQ:ARDX), Epizyme Inc. (NASDAQ:EPZM) and Mersana Therapeutics Inc. (NASDAQ:MRSN). Among private companies, he chairs Cydan Development Inc....
BioCentury | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

...Willem Scheele as CMO. He succeeds interim CMO Shi Yin Foo, who is CMO of Cydan II Inc....
BioCentury | Jan 5, 2019
Finance

Longitude takes a spin with Cydan

...Longitude Capital's first foray into a Cydan Development Inc. spinout came Thursday when Cydan launched Tiburio Therapeutics Inc...
...former Head of Endocrinology R&D Michael Culler will chair Tiburio’s SAB, Ceesay said. Jennie Walters, Staff Writer Cydan II Inc. Ipsen...
BioCentury | Jan 4, 2019
Financial News

Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

...plans to develop for rare neuroendocrine tumors and rare endocrine diseases. Tiburio spun out of Cydan Development Inc....
BioCentury | Jan 4, 2019
Company News

Codiak, Jazz to develop exosomes against tricky oncogenes

...market close. Codiak BioSciences Inc., Cambridge, Mass. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Business: Cancer Jennie Walters Cydan II Inc. Jazz...
BioCentury | Jan 3, 2019
Financial News

Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

...plans to develop for rare neuroendocrine tumors and rare endocrine diseases. Tiburio spun out of Cydan Development Inc....
...be eligible for development and commercial milestones, plus royalties. Ceesay declined to disclose financial terms. Jennie Walters Cydan II Inc. Dopamine...
BioCentury | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

...and nanotechnology at the Technical University of Denmark (Kongens Lyngby, Denmark). Rare genetic disease accelerator Cydan Development Inc....
BioCentury | Oct 20, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...from academia, not-for-profits and industry. CEO Chris Adams told BioCentury the accelerator's new investment vehicle, Cydan II Inc....
...was director of CMC at Ascendis Pharma A/S (NASDAQ:ASND). Cydan Development Inc. , Cambridge, Mass. Chris Lieu IMR-687 VTS-270 Ascendis Pharma A/S Cydan II Inc. Imara...
BioCentury | Oct 20, 2017
Finance

Fast inflections

...Longitude Capital joined Cydan Development Inc. ’s syndicate with the expectation that spinouts from the rare disease accelerator...
...to six additional spinouts, and expects to announce its third newco next year. Virginia Li, Staff Writer Cydan II Inc. Vtesse...
BioCentury | Oct 17, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...from academia, not-for-profits and industry. CEO Chris Adams told BioCentury the accelerator's new investment vehicle, Cydan II Inc....
...Bristol-Myers Squibb Co. (NYSE:BMY) acquired. Svenstrup was director of CMC at Ascendis Pharma A/S (NASDAQ:ASND). Chris Lieu IMR-687 VTS-270 Cydan II Inc. Imara...
Items per page:
1 - 10 of 21